3rd Quarter - Report — TERUMO BCT, INC. for TERUMO BCT, INC. (2026)

Firm

TERUMO BCT, INC.

Client

TERUMO BCT, INC.

Income

—

Expenses

$20,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Global trade and tariffs

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

S.721/H.R. 5178 - Sickle Cell Disease Comprehensive Care Act Blood and cell collection, storage, and processing Blood donation supply and quality

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5178 (119th), S. 721 (119th)

Medicare/Medicaid MMM

Medicaid Eligibility, work and community engagement requirements

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.